OTCMKTS:PTIX - Protagenic Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.30 0.00 (0.00 %)
(As of 02/20/2019 08:12 AM ET)
Previous Close$2.30
Today's Range$2.30 - $2.30
52-Week Range$1.25 - $2.50
Volume1 shs
Average Volume7 shs
Market Capitalization$23.60 million
P/E RatioN/A
Dividend YieldN/A
Beta-9.02
Protagenic Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics to treat central nervous system disorders. Its lead drug candidate is PT00114, which is in clinical proof-of-concept studies for the treatment-resistant depression and/or post-traumatic stress disorder. The company is based in New York, New York.

Receive PTIX News and Ratings via Email

Sign-up to receive the latest news and ratings for PTIX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Business services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PTIX
CUSIPN/A
Phone212-994-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.12 per share

Profitability

Net Income$-2,250,000.00

Miscellaneous

Employees3
Market Cap$23.60 million
OptionableNot Optionable

Protagenic Therapeutics (OTCMKTS:PTIX) Frequently Asked Questions

What is Protagenic Therapeutics' stock symbol?

Protagenic Therapeutics trades on the OTCMKTS under the ticker symbol "PTIX."

How were Protagenic Therapeutics' earnings last quarter?

Protagenic Therapeutics Inc (OTCMKTS:PTIX) released its quarterly earnings data on Tuesday, May, 15th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter. View Protagenic Therapeutics' Earnings History.

Has Protagenic Therapeutics been receiving favorable news coverage?

Media headlines about PTIX stock have been trending somewhat positive on Wednesday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Protagenic Therapeutics earned a news impact score of 1.4 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are some of Protagenic Therapeutics' key competitors?

Who are Protagenic Therapeutics' key executives?

Protagenic Therapeutics' management team includes the folowing people:
  • Dr. Garo H. Armen, Co-Founder & Exec. Chairman (Age 65)
  • Dr. Alexander K. Arrow C.F.A., M.D., CFA, CFO, Compliance Officer & Sec. (Age 47)
  • Dr. Dalia Barsyte, Chief Technology Advisor
  • Dr. David A. Lovejoy, Chief Scientific Advisor
  • Ms. Christina Fam Faragalla, Director of Project Management

How do I buy shares of Protagenic Therapeutics?

Shares of PTIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Protagenic Therapeutics' stock price today?

One share of PTIX stock can currently be purchased for approximately $2.30.

How big of a company is Protagenic Therapeutics?

Protagenic Therapeutics has a market capitalization of $23.60 million. Protagenic Therapeutics employs 3 workers across the globe.

What is Protagenic Therapeutics' official website?

The official website for Protagenic Therapeutics is http://www.protagenic.com.

How can I contact Protagenic Therapeutics?

Protagenic Therapeutics' mailing address is 149 FIFTH AVENUE SUITE 500, NEW YORK NY, 10010. The biotechnology company can be reached via phone at 212-994-8200 or via email at [email protected]


MarketBeat Community Rating for Protagenic Therapeutics (OTCMKTS PTIX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  41 (Vote Outperform)
Underperform Votes:  44 (Vote Underperform)
Total Votes:  85
MarketBeat's community ratings are surveys of what our community members think about Protagenic Therapeutics and other stocks. Vote "Outperform" if you believe PTIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel